Home > Healthcare > Biotechnology > Biotechnology R&D > Autologous Cell Therapy Market

Autologous Cell Therapy Market Trends

Report ID: GMI6031
Published Date: Jun 2023
Report Format: PDF

Download Free Sample

Autologous Cell Therapy Market Trends

Increasing prevalence of chronic diseases such as blood cancer, autoimmune disorders, orthopedic conditions among others is slated to boost the market revenue. For instance, according to a recent study published by University of Oxford, autoimmune diseases affect around 10% of the global population and in UK around 1 in 10 individuals are affected with autoimmune disorder.

Thus, growing prevalence of serve chronic disease is propelling the demand for autologous cell therapy. Furthermore, autologous cell therapy promote tissue regeneration, enhance immune responses and provide personalized treatments along with regenerative and immunomodulatory properties lead to improved treatment outcomes, reduced risk of rejection or adverse reactions, and potentially lower long-term healthcare costs.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for autologous cell therapy accounted for USD 12.9 billion in 2022 and will reach USD 38 billion by 2032, owing to the rising prevalence of chronic disease coupled with growing demand for personalized treatment.

The bone marrow segment is expected to register USD 16.5 billion by end of 2032, as cells sourced from bone marrow for autologous cell therapy reduces the risk of immune rejection or adverse reactions.

North America autologous cell therapy market accounted for over 42.2% revenue share in 2022 and will continue growing through 2032, backed by the presence of well-established healthcare infrastructure, key market players, and academic institutions in the region.

Lonza Group AG, Novartis AG, Bristol-Myers Squibb Company, Corning Incorporated among others.